Sentinel™ Trial: A Prospective Study Evaluating the Performance and Clinical Benefit of Personalized ctDNA-based MRD Testing to Detect Recurrence and Monitor Treatment Response in Patients With Solid Tumors

TERMINATED

Status

295

Enrollment

INDUSTRY

Sponsor class

Stopped Sentinel MRD test offers no additional or increased benefits to patients compared to current marketed alternatives

Conditions

Strata Oncology